Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 315

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Improvement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20)

Devauchelle‐Pensec, Valérie, Pennec, Yvon, Morvan, Johanne, Pers, Jacques‐Olivier, Daridon, Capucine, Jousse‐Joulin, Sandrine, Roudaut, Anne, Jamin, Christophe, Renaudineau, Yves, Roué, Isabelle Quintin, Cochener, Béatrice, Youinou, Pierre, Saraux, Alain · 2007 · Arthritis Care & Research

Abstract

Objective: There is evidence to support a dominant role for B cells in the pathophysiology of primary Sjögren's syndrome (SS). Therefore, we evaluated the safety and efficacy of anti‐CD20 monoclonal antibody. Methods: Sixteen patients who met the new American‐European Consensus Group criteria for primary SS and scored >50 on at least 2 of 4 visual analog scales (VAS; 100 mm) evaluating global disease, pain, fatigue, and global dryness received infusions of low‐dose rituximab (375 mg/m 2) at weeks 0 and 1 without steroid premedication. Results: Slow rituximab infusions (100 mg/hour) were well tolerated, with only 1 patient experiencing serum sickness–like disease. There was a dramatic reduction in B cells of the blood and salivary gland (SG). At week 12, VAS scores with respect to fatigue and dryness (P < 0.05), tender point count (P < 0.035), and quality of life as evaluated by the Short Form 36 questionnaire (SF‐36; P < 0.001) were significantly improved. At week 36, significant improvements were noted in the 4 VAS scores (P < 0.05), tender joint count (P = 0.017), tender point count (P = 0.027), and SF‐36 (P < 0.03). Pulmonary manifestations were ameliorated in 1 patient. Patients with improvements on at least 3 of the 4 VAS scores at any visit (n = 11) had a shorter disease duration than the other patients (n = 5; mean ± SD duration 3.8 ± 5.4 versus 30.1 ± 29.5 years; P = 0.02). Conclusion: Low‐dose rituximab infusions were well tolerated without the benefit of steroids. Infusions induced a rapid depletion of B cells in the blood and SG and could improve primary SS. Controlled studies are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.22536

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 315

Metadata

Authors
Devauchelle‐Pensec, V., Pennec, Y., Morvan, J., Pers, J., Daridon, C., Jousse‐Joulin, S., Roudaut, A., Jamin, C., Renaudineau, Y., Roué, I. Q., Cochener, B., Youinou, P., & Saraux, A.
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2007-02-28
Volume
57
Issue
2
Pages
310-317
ISSN
  • 0893-7524 (ISSN-L)
  • 1529-0123
OpenAlex
W2024235155
Cited by
315
References
29
FWCI
16.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.